YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Company Logo Up from about US$300 million in 2025 across the US, EU4, UK and Japan, as Merck's WELIREG, the first oral targeted PCPG therapy, faces pipeline rivals from Novartis, Jazz and Perspective. Dublin, Oct. 08, 2026 (GLOBE NEWSWIRE)…
BioMarin, Jazz Pharmaceuticals, and Otsuka CEOs to Join NORD CEO to Examine What it Takes to Turn Scientific Advancements into Patient Progress WASHINGTON, Oct. 6, 2026 /PRNewswire/ -- The National Organization for Rare Disorders (NORD®) t…
Entera Bio Ltd. Former Gilead and Amgen executive joins Entera with over 35 years of experience advancing and commercializing impactful and blockbuster therapies TEL AVIV, Israel, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:…
Q2 Earnings Outperformers: Jazz Pharmaceuticals (NASDAQ:JAZZ) And The Rest Of The Pharmaceuticals Stocks As the Q2 earnings season wraps, let's dig into this quarter's best and worst performers in the pharmaceuticals industry, including Ja…
Target upgraded, Moderna downgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled b…
AbCellera Biologics ABCL has delivered a sharp rally over the past three months, with the stock soaring 121% compared with the industry's 6.6% growth. The move has been driven primarily by a combination of strong clinical progress for its…
[IPO Initial Public Offering on Financial Stock Market Chart 3D render] gonin Iambic Therapeutics, an AI-driven drug discovery company backed by Nvidia (NVDA [https://seekingalpha.com/symbol/NVDA]), filed for a U.S. initial public offering…
Iambic Therapeutics, Inc., an AI drug discovery company backed by Nvidia Corp.(NASDAQ:NVDA) and the Qatar Investment Authority, filed for an initial public offering, according to an S-1 filing with the SEC on Monday. Plans to List on Nasda…
[Scientists inside a laboratory] Hinterhaus Productions The Food and Drug Administration and Duke-Margolis Institute for Health Policy will convene a public workshop this month to examine one of the most difficult questions in rare disease…
On September 15, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) completed its acquisition of privately held Actio Biosciences for $820 million upfront, adding a clinical-stage epilepsy drug called ABS-1230 to its rare disease pipeline. The deal la…
Jazz Pharmaceuticals (NasdaqGS:JAZZ) is assessing new trials of newly approved cancer drug Ziihera beyond gastroesophageal adenocarcinoma. The company is preparing development plans to study Ziihera in breast cancer, colorectal cancer, and…
3 Cash-Producing Stocks We're Skeptical Of While strong cash flow is a key indicator of stability, it doesn't always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak comp…
2 Reasons to Avoid JAZZ and 1 Stock to Buy Instead Jazz Pharmaceuticals's 29.7% return over the past six months has outpaced the S&P 500 by 17%, and its stock price has climbed to $240.49 per share. This was partly thanks to its solid quar…
Jazz Pharmaceuticals (JAZZ) could see long-term value from Ziihera's pursuit of additional indicatio PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium n…
Amgen AMGN announced positive results from a phase III study that evaluated its lung cancer therapy Imdelltra (tarlatamab) in combination with AstraZeneca's AZN blockbuster immunotherapy Imfinzi (durvalumab) for certain patients with exten…
1 Value Stock with Exciting Potential and 2 We Brush Off The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are gen…
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) reported that Ziihera plus chemotherapy produced a statistically significant and clinically meaningful overall-survival benefit over trastuzumab plus chemotherapy in the Phase 3 HERIZON-GEA-01 trial.…
DUBLIN, Sept. 2, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that company management will participate in fireside chats at the following investor conferences: Wells Fargo 21st Annual Healthcare Conference o…
A month has gone by since the last earnings report for Jazz Pharmaceuticals (JAZZ). Shares have lost about 6.9% in that time frame, underperforming the S&P 500. But investors have to be wondering, will the recent negative trend continue le…
RAPPERSWIL, SWITZERLAND - September 1, 2026 (NEWMEDIAWIRE) - Neovii Pharmaceuticals AG today announced the appointment of Duncan Ferguson as Chief Commercial Officer (CCO), effective 1 September 2026. Ferguson joins the company at a pivota…
Stocks making big moves yesterday: Jazz Pharmaceuticals, SAIC, Herbalife, AGCO, and Deere Check out the companies making headlines yesterday: Jazz Pharmaceuticals (NASDAQ:JAZZ): Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) rose by…
Axsome Therapeutics AXSM announced that it has dosed the first patient in the phase III SUMMIT study evaluating AXS-05 for the treatment of smoking cessation. The randomized, double-blind, placebo-controlled phase III SUMMIT study is desig…
Jazz Pharmaceuticals JAZZ announced second interim top-line overall survival (OS) results from the phase III HERIZON-GEA-01 study, which evaluated different combination regimens involving its marketed drug, Ziihera (zanidatamab) as a first…
Jazz Pharmaceuticals (JAZZ) Stock Trades Up, Here Is Why What Happened? Shares of biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) jumped 2.5% in the afternoon session after the company announced positive Phase 3 HERIZON-GEA-01 trial r…
HERIZON-GEA-01 results reinforce recently FDA-approved Ziihera as the definitive HER2-targeted backbone therapy in first-line GEA Longer follow up of Ziihera plus tislelizumab and chemotherapy shows improved OS hazard ratio, further suppor…
Jazz Pharmaceuticals' (JAZZ) shares are up about 45% year to date, but may still have the potential PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium ne…
Jazz Pharmaceuticals recently secured FDA approval for Ziihera (zanidatamab-hrii)–based regimens in first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive gastroesophageal adenocarcinoma, supported by…
* Jazz Pharmaceuticals (JAZZ [https://seekingalpha.com/symbol/JAZZ]) announced [https://seekingalpha.com/pr/20631578-jazz-pharmaceuticals-announces-pricing-of-upsized-private-offering-of-1_1-billion-of-1_875]the pricing of $1.1B aggregate…
DUBLIN, Aug. 27, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") announced the pricing of $1.1 billion aggregate principal amount of 1.875% exchangeable senior notes due 2032 (the "notes") in a private…
The Trump administration is expected to announce a series of drug pricing deals with several mid-size biotech companies as early as Monday, adding to similar agreements reached with Big Pharma since late last year, Bloomberg News reported…
Jazz Pharmaceuticals JAZZ announced that the FDA has approved a label expansion of its marketed drug, Ziihera (zanidatamab-hrii), for the first-line treatment of adults with unresectable locally advanced or metastatic HER2-positive gastroe…
The stock market rose Tuesday amid lower oil prices and yields, but cautiously heading into Fed inflation data and Nvidia earnings. Continue Reading
DUBLIN, Aug. 26, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz Pharmaceuticals") today announced that Jazz Investments I Limited, its wholly-owned subsidiary (the "Issuer"), intends to offer, subject to market conditi…
The stock market rose Tuesday amid lower oil prices and yields, but cautiously heading into Fed inflation data and Nvidia earnings. Continue Reading
Jazz stock bounced off its buy zone Tuesday after the FDA approved its drug, Ziihera, to treat a form of stomach cancer. Continue Reading
Ziihera plus tislelizumab and chemotherapy approved for first-line treatment of all HER2+ GEA patients (IHC 3+ and IHC 2+/ISH+) regardless of PD-L1 status, establishing a new standard of care in front-line GEA Company to host investor webc…